$CLRO Cashflow Statement | Understand Stock

$CLRO

$5.57 +$0.58 (11.62%) Close

$CLRO Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense
Amortization of right of use of assets
Share-based compensation expense
Provision for doubtful accounts, net
Change of inventory to net realizable value
Non-cash interest expense
Loss on disposal of assets
Gain recognized on Paycheck Protection Plan Loan forgiveness
Patent license proceeds
Changes in operating assets and liabilities:
Receivables
Legal settlement receivable
Inventories
Prepaid expenses and other assets
Accounts payable
Accrued liabilities
Income taxes receivable
Deferred product revenue
Operating lease liabilities
Other long-term liabilities
Net cash provided by (used in) operating activities
Net cash used in operating activities
Cash flows from investing activities:
Proceeds from maturities and sales of marketable securities
Net cash provided by (used in) investing activities
Purchases of marketable securities
Purchase of property and equipment
Purchase of intangibles
Capitalized patent defense costs
Net cash provided by investing activities
Cash flows from financing activities:
Dividend payment
Principal payments of long-term debt
Proceeds from issuance of short-term notes
Proceeds from Paycheck Protection Program loan
Proceeds from equity-based compensation programs
Gross proceeds from issuance of common stock and warrants
Costs of issuance of common stock and warrants
Net cash used in financing activities

Net increase (decrease) in cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents
Net decrease in cash and cash equivalents
Proceeds from sale of stock
Proceeds from issuance of convertible note
Purchases of outstanding warrants
Proceeds from equity-based compensation programs
Net cash provided by (used) in financing activities
Cash flows from discontinued operations
Net cash provided by operating activities
Net cash provided by investing activities
Net cash provided by financing activities
Net cash provided by discontinued operations
Effect of exchange rate changes on cash and cash equivalents and restricted cash
Net decrease in cash and cash equivalents and restricted cash
Cash and cash equivalents and restricted cash at the beginning of the year
Cash and cash equivalents and restricted cash at the end of the year
Supplemental disclosure of cash flow information:
Cash paid for income taxes
Cash paid for interest
Right-of-use assets obtained in exchange for lease obligations
Interest paid as non-cash dividend
Conversion of debt to Series B Preferred stock

Comments